USPTO 2015–2025 USPTO PatentsView US Corporation

Biogen MA Inc.

USPTO PatentsView assignee record - 247 granted patents across 39 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Explore the portfolio See the ranking

247

Total patents granted

CPC technology areas

19.6

Avg claims per patent

-4%

5-year filing velocity

The verdict

Biogen holds 247 US patents across 39 technology areas, rank #1,662 of 50,000 tracked assignees.

#1,662
of 50,000 US assignees by volume: Top 6%
by Innovation Score (57.0/100): 19.6
avg claims per patent: -4%
filing velocity, last 5 yrs

Portfolio overview

Biogen MA Inc. has been granted 247 US utility patents between 2015 and 2025, placing Biogen MA Inc. at rank #1,662 across all assignees tracked by PlainPatent. This portfolio spans 39 distinct Cooperative Patent Classification (CPC) subclasses, averaging 19.6 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a US Corporation, Biogen MA Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Biogen sits between Oregon Health & Science University (248 patents, rank #1,658) and J. Choo Limited (247 patents, rank #1,666) - the closest US assignees by grant volume. The composite Innovation Score of 57.0/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 121 grants, compared with 126 in the 2015–2019 window, a -4% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Biogen MA Inc.'s 19.6 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 39 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Biogen MA Inc. against peers pursuing similar technology classes.

Oregon Health & S…

248
Richemont Interna…

248
Teradata US

248
Water Pik

248
Cambridge Enterpr…

247
H LEE Moffitt Can…

247
Honeywell Federal…

247
J Choo

247
Biogen MA ◀

247

What this shows Biogen holds 247 patents at rank #1,662, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Biogen

By rank, the assignees closest to #1,662 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Biogen's primary technology class.

Biogen's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

57 Top 6% higher than 94% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Biogen MA Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	12	4.9%
2016	24	9.7%
2017	38	15.4%
2018	21	8.5%
2019	31	12.6%
2020	20	8.1%
2021	34	13.8%
2022	21	8.5%
2023	18	7.3%
2024	14	5.7%
2025	14	5.7%

Which technologies does Biogen MA Inc. patent most?

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 152

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 127

C07K - PEPTIDES 95

C07D - HETEROCYCLIC COMPOUNDS 71

G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 57

C12N - MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA 42

Y02A - TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE 33

C07C - ACYCLIC OR CARBOCYCLIC COMPOUNDS 19

C07B - GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR 18

C07F - ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM 15

C12Q - MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES 10

A61M - DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR 10

A61B - DIAGNOSIS; SURGERY; IDENTIFICATION 10

C12P - FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE 10

C07H - SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS 7

Top 15 of 39 technology areas

Patent Moat Analysis

Portfolio Volume Moderate

Tech Breadth Multi-domain

Claim Depth Standard

Velocity Declining

Where it ranks

Overall rank by patents

#1,662

Across all tracked assignees

Innovation Score

57.0 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Biogen MA Inc. hold?

Biogen MA Inc. holds 247 US granted patents filed between 2015 and 2025, spanning 39 technology areas.

What is Biogen MA Inc.'s Innovation Score?

Biogen MA Inc. has an Innovation Score of 57.0 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Biogen MA Inc. focus on?

Biogen MA Inc.'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 152 patents. The company has filed patents in 39 CPC subclasses total.

Is Biogen MA Inc.'s patent filing rate increasing or decreasing?

Biogen MA Inc.'s recent filing velocity is -4% compared to the prior five-year period. Filing activity has slowed relative to earlier years.

What does claim depth mean for Biogen MA Inc.'s patents?

Biogen MA Inc.'s patents average 19.6 claims each. This falls within the standard range, providing solid legal coverage.

How is the Biogen MA Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Biogen's 247 grants land it in the top 6% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - Biogen ranks #1,662 of 50,000. Top 50 holders
Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.